ES2191016T3 - Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial. - Google Patents

Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.

Info

Publication number
ES2191016T3
ES2191016T3 ES93921646T ES93921646T ES2191016T3 ES 2191016 T3 ES2191016 T3 ES 2191016T3 ES 93921646 T ES93921646 T ES 93921646T ES 93921646 T ES93921646 T ES 93921646T ES 2191016 T3 ES2191016 T3 ES 2191016T3
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
pct
synctial
neutralizing monoclonal
respiratory virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921646T
Other languages
English (en)
Inventor
Dennis R Burton
Carlos F Barbas Iii
Robert M Chanock
Brian R Murphy
James E Crowe Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Scripps Research Institute
Original Assignee
US Department of Health and Human Services
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Scripps Research Institute filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2191016T3 publication Critical patent/ES2191016T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

SE DESCRIBEN ANTICUERPOS MONOCLONALES HUMANOS Y FRAGMENTOS DEL MISMO QUE ENLAZAN Y NEUTRALIZAN LOS SUBGRUPOS A Y B ANTIGENICOS DEL VIRUS SINCITIAL RESPIRATORIO. TAMBIEN SE DESCRIBEN METODOS DE DIAGNOSTICO E INMUNOTERAPEUTICOS DE UTILIZACION DE ANTICUERPOS MONOCLONALES ASI COMO LINEAS CELULARES QUE PRODUCEN LOS ANTICUERPOS MONOCLONALES.
ES93921646T 1992-09-16 1993-09-16 Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial. Expired - Lifetime ES2191016T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94551592A 1992-09-16 1992-09-16

Publications (1)

Publication Number Publication Date
ES2191016T3 true ES2191016T3 (es) 2003-09-01

Family

ID=25483204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921646T Expired - Lifetime ES2191016T3 (es) 1992-09-16 1993-09-16 Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.

Country Status (12)

Country Link
US (1) US5762905A (es)
EP (1) EP0671927B1 (es)
JP (1) JP3976333B2 (es)
AT (1) ATE231002T1 (es)
AU (1) AU686113B2 (es)
CA (1) CA2144043C (es)
DE (1) DE69332643T2 (es)
DK (1) DK0671927T3 (es)
ES (1) ES2191016T3 (es)
FI (2) FI108991B (es)
NO (1) NO323768B1 (es)
WO (1) WO1994006448A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU7075496A (en) 1995-09-18 1997-04-09 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
EP0977590A4 (en) * 1996-11-01 2001-03-14 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
FR2758331B1 (fr) * 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
ATE276763T1 (de) 1998-07-13 2004-10-15 Univ Texas Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
CO5280147A1 (es) * 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001055217A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
JP2003525061A (ja) 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
US20050175986A1 (en) * 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
JP2004511807A (ja) * 2000-10-17 2004-04-15 ベッスト−テスト　アンパーツゼルスカブ 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2003063767A2 (en) * 2001-11-02 2003-08-07 Centocor Rsv proteins, antibodies, compositions, methods and uses
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US6919077B2 (en) * 2002-09-27 2005-07-19 Aids Research, Llc LFA-1 alpha subunit antibodies and methods of use
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP2008518936A (ja) * 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Ｒｓｖ感染症および関連状態を予防および治療する方法
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
CN101679513A (zh) * 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
IL210093A0 (en) 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
CL2011003002A1 (es) * 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11312761B2 (en) 2016-10-21 2022-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018075974A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
TWI754157B (zh) 2018-07-25 2022-02-01 大陸商信達生物製藥（蘇州）有限公司 抗ｔｉｇｉｔ抗體及其用途
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US20230105029A1 (en) 2020-02-27 2023-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
AU2021271960A1 (en) 2020-05-12 2023-02-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ST2 antigen binding protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
WO1991016074A1 (en) * 1990-04-19 1991-10-31 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
ATE175123T1 (de) * 1990-07-19 1999-01-15 Us Commerce Verbesserte immunotherapeutische methode zur verhinderung oder behandlung viraler krankheiten der atemwege
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man

Also Published As

Publication number Publication date
DE69332643D1 (de) 2003-02-20
CA2144043A1 (en) 1994-03-31
ATE231002T1 (de) 2003-02-15
NO950881D0 (no) 1995-03-07
US5762905A (en) 1998-06-09
DE69332643T2 (de) 2003-11-27
FI20020184A (fi) 2002-01-31
EP0671927A1 (en) 1995-09-20
CA2144043C (en) 2005-01-18
FI951164A0 (fi) 1995-03-13
WO1994006448A1 (en) 1994-03-31
EP0671927A4 (en) 1997-05-21
FI108991B (fi) 2002-05-15
DK0671927T3 (da) 2003-04-22
AU4927193A (en) 1994-04-12
FI111553B (fi) 2003-08-15
EP0671927B1 (en) 2003-01-15
JPH08505520A (ja) 1996-06-18
AU686113B2 (en) 1998-02-05
FI951164A (fi) 1995-05-12
JP3976333B2 (ja) 2007-09-19
NO950881L (no) 1995-05-15
NO323768B1 (no) 2007-07-02

Similar Documents

Publication Publication Date Title
ES2191016T3 (es) Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
FI951488A0 (fi) Ihmisen immuunikatoviruksen vastaiset ihmisen neutraloivat monoklonaaliset vasta-aineet
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69426077D1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
HK1048831A1 (en) Human ctla-4 antibodies and their uses
BR9809656A (pt) Composição imunopotencializante
FI972703A (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EA199900342A1 (ru) Способ создания активного иммунитета вакцинным конъюгатом
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
ATE359814T1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
EP0836480A4 (en) COMPOSITIONS THAT PROVIDE ADP-RIBOSYL TRANSFERASE ACTIVITY AND METHODS FOR THEIR PRODUCTION AND USE
IL117151A0 (en) Novel antigen
GB9715177D0 (en) Medicament
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
AU8501191A (en) Cross-reactive influenza a immunization
DE69617255D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung
AU2579600A (en) Product and method for obtaining specific immunisation with one or more antigens
UA91182C2 (ru) Антитело, которое специфично связывается с фактором роста соединительной ткани (ctgf)
NO980721L (no) Vaksiner